Abstract
Carcinomatous meningitis occurs during the late phase in the development of cancers and remains difficult to treat. In addition to systemic treatments, intrathecal therapy is rarely used because of its limited effectiveness. New knowledge on the physiology of intracranial fluid and on pharmacokinetics of intrathecal injection, the availability of implantable pumps for continuous infusion and the advent of new immunotherapies and targeted therapies push towards a renewal of this therapeutic approach, particularly in lung and breast cancers, as well as in malignant melanoma.1877-1203/© 2022 SPLF. Published by Elsevier Masson SAS. All rights reserved.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
